ZYME Stock Overview
A clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Zymeworks Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.20 |
| 52 Week High | US$13.27 |
| 52 Week Low | US$6.46 |
| Beta | 1.19 |
| 11 Month Change | 8.37% |
| 3 Month Change | 31.08% |
| 1 Year Change | 103.08% |
| 33 Year Change | -49.11% |
| 5 Year Change | -55.44% |
| Change since IPO | 1.54% |
Recent News & Updates
Zymeworks Approaching A Moment Of Truth With Zanidatamab
Sep 27Analysts Are Betting On Zymeworks Inc. (NASDAQ:ZYME) With A Big Upgrade This Week
Aug 07
Recent updates
Zymeworks Approaching A Moment Of Truth With Zanidatamab
Sep 27Analysts Are Betting On Zymeworks Inc. (NASDAQ:ZYME) With A Big Upgrade This Week
Aug 07Zymeworks Inc.'s (NASDAQ:ZYME) 27% Share Price Surge Not Quite Adding Up
Jul 26Zymeworks: A Somewhat Complicated Story
Jul 09Zymeworks (NASDAQ:ZYME) Is In A Good Position To Deliver On Growth Plans
Jun 12Zymeworks Inc.'s (NASDAQ:ZYME) Shares Lagging The Industry But So Is The Business
May 03Buy Zymeworks Pioneering Cancer Treatments: Zanidatamab's Promising Data
Apr 18Zymeworks: A Strong Buy Amidst Zanidatamab's Promising Developments
Mar 05Zymeworks: Key Readout For Zanidatamab This Year And ADC Pipeline Expansion
Feb 06Zymeworks: Stock Emerges From Nearly 2 Years In The Doldrums, Thanks To An ADC Tailwind
Jan 31Zymeworks Non-GAAP EPS of -$0.66 beats by $0.31, revenue of $2.6M misses by $1.95M
Nov 08Zymeworks: A Binary Event With BTC Data By End-2022 Which May Trigger Milestone
Oct 26Zymeworks: A Roller Coaster Year
Jul 26Zymeworks And The Blue Falcon Elucidation
May 17Zymeworks Inc. (NYSE:ZYME) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Feb 27Shareholder Returns
| ZYME | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 5.0% | 1.1% | 1.0% |
| 1Y | 103.1% | 20.8% | 33.6% |
Return vs Industry: ZYME exceeded the US Biotechs industry which returned 19.7% over the past year.
Return vs Market: ZYME exceeded the US Market which returned 31.9% over the past year.
Price Volatility
| ZYME volatility | |
|---|---|
| ZYME Average Weekly Movement | 4.3% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ZYME has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ZYME's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 290 | Ken Galbraith | www.zymeworks.com |
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas.
Zymeworks Inc. Fundamentals Summary
| ZYME fundamental statistics | |
|---|---|
| Market cap | US$937.83m |
| Earnings (TTM) | -US$112.51m |
| Revenue (TTM) | US$62.71m |
15.0x
P/S Ratio-8.3x
P/E RatioIs ZYME overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZYME income statement (TTM) | |
|---|---|
| Revenue | US$62.71m |
| Cost of Revenue | US$121.25m |
| Gross Profit | -US$58.55m |
| Other Expenses | US$53.96m |
| Earnings | -US$112.51m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 31, 2024
| Earnings per share (EPS) | -1.58 |
| Gross Margin | -93.37% |
| Net Profit Margin | -179.42% |
| Debt/Equity Ratio | 0% |
How did ZYME perform over the long term?
See historical performance and comparison